Lisa Walter
Stock Analyst at RBC Capital
(2.81)
# 1,691
Out of 5,140 analysts
10
Total ratings
66.67%
Success rate
23.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.63 | +109.70% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $7.69 | +316.12% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $32.29 | +39.36% | 2 | Nov 6, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $15.53 | +151.13% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $469.77 | +24.95% | 2 | Oct 30, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $20.95 | -9.31% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.63
Upside: +109.70%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $7.69
Upside: +316.12%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $32.29
Upside: +39.36%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $15.53
Upside: +151.13%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $469.77
Upside: +24.95%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $20.95
Upside: -9.31%